Cardiac hypertrophy involves the growth of heart muscle cells and is driven by faster protein synthesis which involves increased ribosome biogenesis. However, the signaling pathways that link hypertrophic stimuli to faster ribosome production remain to be identified. Here we have investigated the signaling pathways which promote ribosomal RNA synthesis in cardiomyocytes in response to hypertrophic stimulation. We employed a new non-radioactive labeling approach and show that the hypertrophic agent phenylephrine (PE) stimulates synthesis of 18S rRNA (made by RNA polymerase I) and 5S rRNA (produced by RNA polymerase III) in adult cardiomyocytes. In many settings, rRNA synthesis is driven by rapamycin-sensitive signaling through mammalian target of rapamycin complex 1 (mTORC1). However, the activation of rRNA synthesis by PE is not inhibited by rapamycin, indicating that its regulation involves other signaling pathways. PE stimulates MEK/ERK signaling in these cells. Inhibition of this pathway blocks the ability of PE to activate synthesis of 18S and 5S rRNA. Furthermore, BI-D1870, an inhibitor of the p90 RSK s, protein kinases which are activated by ERK, blocks PE-activated rRNA synthesis, as did a second p90 RSK inhibitor, SL0101. BI-D1870 also inhibits the PE-stimulated association of RNA polymerase I with the rRNA promoter. These findings show that signaling via MEK/ERK/p90 RSK , not mTORC1, drives rRNA synthesis in adult cardiomyocytes undergoing hypertrophy. This is important both for our understanding of the mechanisms that control ribosome production and, potentially, for the management of cardiac hypertrophy.
Introduction
In the adult myocardium, growth is mediated through changes in the size of the cardiomyocytes. A major driver of cell growth is the rate of protein synthesis, reflecting the fact that the majority of dry cell mass is protein. Consistent with this, agents that induce cardiomyocyte growth (hypertrophy) activate protein synthesis (reviewed in [1] ). Cardiac hypertrophy (CH) occurs in response, e.g., to increased load, and is initially adaptive. However, in conditions of continued stress, CH leads to loss of cardiomyocytes and to tissue fibrosis, becoming a major risk factor for heart failure. A better understanding of the molecular mechanisms that link pro-hypertrophic stimuli to increased protein synthesis in cardiomyocytes is needed to develop therapeutic strategies for CH.
Cellular protein synthesis rates are determined both by the overall levels of ribosomes and translation factors ('translational capacity') and by their intrinsic activities ('translational efficiency'). The hypertrophic agonist PE rapidly stimulates protein synthesis in ARVC [2] . This effect is markedly inhibited by rapamycin, indicating that it is mediated through the mammalian target of rapamycin complex 1, mTORC1. Activation of mTORC1 by hypertrophic stimuli such as PE in ARVC is mediated by MEK/ERK signaling [3] [4] [5] [6] . Early studies demonstrated that ribosome content increases in hypertrophying rat heart and that increased ribosome synthesis is an early event in hypertrophy [7, 8] . However, it is unclear how hypertrophic stimuli promote ribosome biogenesis in cardiomyocytes.
Production of new ribosomes requires synthesis of four ribosomal RNAs (rRNAs) and about 80 ribosomal proteins (Rps) [9] . The three larger rRNAs are made in the nucleolus by RNA polymerase I (Pol I) as a precursor, processing of which yields the mature 5.8S, 18S and 28S rRNAs. The 5S rRNA is made by Pol III. Studies in cell lines have revealed that mTORC1 can regulate Pol I and Pol III [9] [10] [11] .
Previous work on ribosome biogenesis in cardiomyocytes used neonatal cardiomyocytes (e.g., [12] ), which are far easier to make and work with than adult cardiomyocytes. Here, we have studied the regulation of rRNA synthesis in primary adult rat cardiomyocytes, where PE drives cell growth [13] . We show that PE stimulates the synthesis of the 18S and 5S rRNAs, implying that it activates Pol I and Pol III, respectively. These effects are blocked by inhibition of MEK, indicating a requirement for MEK/ERK signaling. However, PE-activated rRNA synthesis is not blocked by rapamycin indicating that, unusually, mTORC1 does not mediate the activation of rRNA production in this setting. Instead, the stimulation of rRNA synthesis by PE requires the activity of p90 RSK s, kinases downstream of ERK [14] . Thus, in cardiomyocytes stimulated with a hypertrophic agonist, MEK/ERK/p90 RSK signaling, and not mTORC1, appears to be the major driver of activated rRNA synthesis.
Materials and methods

Materials
Chemicals for cardiomyocyte isolation were purchased from BDHMerck (Poole, UK) or Sigma-Aldrich unless otherwise stated. Bovine serum albumin (BSA, fraction V) was from Boehringer Mannheim and Collagenase (type II) from Worthington Biochemical, New Jersey. Nylon monofilament filter cloth was from Cadish Precision Meshes. Dialysis tubing of size 5 (MW cut-off: 12-14000 Da) was from Medicell International. One mL pastettes were from Alpha Laboratories. Vacuum filter unit Stericup sterile PES membrane (0.22 μm pore size) was from Millipore.
All chemicals and biochemicals for RNA isolation, including 4-thiouridine (4SU), and for the chromatin immunoprecipitation assay were obtained from Sigma-Aldrich unless otherwise stated. Tissue culture reagents were provided by Invitrogen. Trizol was from Invitrogen and EZ-Link Biotin-HPDP was from Pierce. Magnetic Porous Glass (MPG) Streptavidin beads were purchased from PUREBiotech. Actinomycin-D, PP242 and rapamycin were supplied by Calbiochem, PD184352 from Toronto Research Chemicals, and AZD6244 from Selleck Chemicals. BI-D1870 was obtained from the Division of Signal Transduction Therapy, College of Life Sciences, University of Dundee (UK). A769662 and SL0101 were from TOCRIS Bioscience. L-[ All phosphospecific antibodies and anti-ribosomal protein S6 were from Cell Signaling Technology. Anti-α-tubulin and anti-UBF (H-300) were from Santa Cruz Biotechnology, as were antibodies for IP of Pol I (sc-46699) and Pol II (sc-47701). Appropriate marker proteins were included on all gels and immunoblots, and were used to ensure that the antibodies did indeed detect the protein bands of the expected sizes.
Preparation, maintenance and treatment of ARVC
Adult rat ventricular cardiomyocytes were isolated and maintained in culture as described [15, 16] . Adult male Sprague-Dawley rats (250-300 g) were from the Biomedical Research Facility, University of Southampton.
Assay of uridine uptake into ARVC
Uridine transport was monitored in cultured ARVC cells in medium either containing or lacking Na + ions, using a method based on those used in earlier studies [17] [18] [19] .
Analysis of RNA dynamics using 4SU labeling
The synthesis and decay of labeled RNA were isolated and measured as previously described [20, 21] . Briefly, 4SU is incorporated into newly-synthesized RNA; following cell lysis, 4SU tagged RNA is covalently coupled to biotin, and isolated on streptavidin beads. After reverse-transcription to cDNA, the quantity of any RNA of interest can be determined by real-time PCR using appropriate primers.
qChIP analysis
Chromatin immunoprecipitation (ChIP) was performed as described previously with modifications [22, 23] . Cross-linking was achieved with 1% formaldehyde for 5 min at an ambient temperature and the cells were sonicated eighteen times for 30 s.
Primers for qPCR analysis of ChIP reactions were β-actin (Primerdesign, Southampton, UK), ENH (sense: AGGAGGCCGGGCA AGCA, antisense: CCTCCTTGTTAGAGACCGTCCTTAA), UCE (sense: AGTTGTTCCTTTGAGGTCCGGT, antisense: AGGAAAGTGACAGGCCAC AGAG) and CORE (sense: AGTTGTTCCTTTGAGGTCCGGT, antisense: CAGCCTTAAATCGAAAGGGTCT). The relative level of DNA binding was analysed using primers specific for the indicated regions of the Pol I promoter by qRT-PCR. Average values of precipitated DNA were normalized to input control.
Results and discussion
PE stimulates the synthesis of new rRNAs in ARVC
We applied a non-radioactive procedure to tag and quantify newly-made rRNA whereby cells are incubated with 4SU which is incorporated into new RNA molecules. Following cell lysis, labeled RNA molecules are covalently linked to biotin and then isolated. After reverse transcription (RT), quantitative real-time PCR (RT-qPCR) is used to measure the levels of any RNA molecule of interest.
To assess whether transferring the cells to medium containing 4SU affected their response to PE, we incubated ARVC for 30 min in medium containing or lacking 4SU to treatment with PE for times up to 1 h. As expected from our earlier studies [2] , PE rapidly induced the phosphorylation (activation) of ERK (Fig. 1A) . The presence of 4SU did not affect this. To assess activation of mTORC1 signaling, we looked at the phosphorylation of Rp S6 (Fig. 1A) . As reported earlier [2] , PE increased S6 phosphorylation and neither the timing nor the extent of this response was affected by 4SU (Fig. 1A) .
Activation of rRNA transcription has previously been shown to be slow in neonatal cardiomyocytes [12] . Therefore, to assess whether PE activates rRNA synthesis, ARVC were treated with PE for 20 h prior to the addition of 4SU. In some cases, cells were treated with actinomycin D (2μg/mL), which inhibits transcription by Pol I, Pol II and Pol III, prior to addition of 4SU. In the absence of actinomycin D, we observed labeling of transcripts made by each of these polymerases (18S rRNA, Pol I; actin, Pol II; and 5S rRNA, Pol III; Fig. 1B ). Incorporation of 4SU into each of them was enhanced by PE, indicating that PE stimulates the transcription of each of these genes, including rRNAs. Importantly labeling was completely blocked by actinomycin D (Fig. 1B) , confirming that this method only detects newly-synthesized RNAs.
By 12 h of PE treatment, a small increase in the labeling of 18S rRNA was observed (Fig. 1C ), but no significant changes in 5S or actin were apparent (Fig. 1C) . After 24 h treatment, much more robust increases in all three were observed (Fig. 1C) ; we therefore selected this as the time-point for further experiments.
Previous work, using neonatal rat cardiomyocytes [12, 24] , indicated that hypertrophic stimuli increase the cellular levels of upstream binding factor (UBF; a component of the Pol I machinery) and Brf1 (a component of TFIIIB, which is a Pol III-specific transcription factor). UBF levels were also increased in vivo after one week of aortic constriction [25] . However, although PE activated synthesis of both 18S rRNA and 5S rRNA by 24 h, there was no detectable change in levels of UBF or Brf1 (Fig. 1D) . Thus, stimulation of rRNA synthesis by PE in ARVC does not require increased levels of UBF or Brf1, but likely involves activation of pre-existing components of the Pol I/III machinery.
Before its incorporation into new RNA molecules, 4SU must enter the cells. It was therefore important to test whether relevant signaling inhibitors affected uridine uptake [26, 27] . Linear uptake of [ 3 H]uridine into ARVC was observed up to 90 s (Fig. 2A) ; linear rates of net uptake are not maintained at longer times, because the nucleoside transporters are equilibrative, not concentrative. PE did not affect the rate of uridine uptake (Fig. 2B) . Because a previous report indicated that very high concentrations of rapamycin (10 μmol/L) inhibited uptake of [ 3 H]uridine into human K562 cells [26] , we first assessed what concentration of rapamycin was required for maximal inhibition of mTORC1 signaling in ARVC, as judged from the phosphorylation of S6 at Ser240/244, specific substrates for the mTORC1-activated S6 kinases [28] . 100 nmol/L was required to block this completely ( into ARVC (Fig. 2B) . Importantly for the work described below, neither the MEK inhibitor AZD6244 [29] (Fig. 2D ) nor the p90 RSK inhibitor BI-D1870
[30] (Fig. 2E ) significantly affected uridine uptake. They can therefore be used to study the regulation of rRNA synthesis without interference from effects on nucleoside transport.
Rapamycin does not block PE-stimulated rRNA synthesis
To examine whether activation of rRNA synthesis by PE requires mTORC1, we studied the effect of rapamycin. Rapamycin decreased both basal and PE-stimulated synthesis of 18S and 5S rRNA (Fig. 3A,B) . The reduced basal rate of labeling likely reflects the partial impairment of uridine uptake observed in Fig. 2B . Importantly, PE still enhanced rRNA labeling in the presence of rapamycin, and to at least the same extent as in its absence. Importantly, given that 100 nmol/L rapamycin completely blocks PE-induced S6 phosphorylation (Fig. 2C ), these findings demonstrate that the PE-induced activation of rRNA synthesis is not mediated via rapamycin-sensitive functions of mTORC1 and thus, in this case, does not involve the S6 kinases which have been suggested to promote rRNA synthesis (reviewed [31] ). Thus, the control of rRNA synthesis by PE in ARVC differs from other settings, where mTORC1 signaling does play a major role [9] . Since some mTOR functions are resistant to rapamycin [32] [33] [34] [35] , we used PP242 [32] which, unlike rapamycin, directly inhibits mTOR's kinase activity and blocks all functions of mTOR. As expected, PP242 blocked PE-induced phosphorylation of S6 at Ser235/236 and Ser240/244 (Suppl. Fig. S1A ) without affecting ERK phosphorylation. PP242 partially inhibited basal rate 18S and 5S rRNA synthesis (Suppl. Fig. S1B ). PP242 also substantially inhibited the PE-activated synthesis of both 18S rRNA and, to a lesser extent, 5S rRNA synthesis (Suppl. Fig. S1B ). Nonetheless, and especially for 5S rRNA synthesis, PE was still able to stimulate rRNA transcription even in the presence of PP242, indicating that events independent of mTOR are involved. PP242, like rapamycin, inhibited [ 3 H]uridine uptake by 40-50% in both PE-treated and control conditions (Suppl. Fig. S1C ). Hence, its inhibitory effect on basal 4SU-labeling of rRNA likely reflects impaired uptake of 4SU, while the partial inhibition of the stimulatory effect of PE may reflect a genuine impairment of rRNA transcription or increased decay of new rRNA given that inhibition of mTOR affects rRNA processing [17] . Such effects could be mediated via mTORC2 or rapamycin-insensitive functions of mTORC1; the lack of a specific mTORC2 inhibitor precludes us from studying this further.
PE enhances rRNA synthesis via MEK signaling
As shown here and previously [2] [3] [4] , PE activates MEK/ERK signaling in ARVC and this mediates its short-term (1-3 h) stimulatory effects on protein synthesis. To test the role of this pathway in rRNA synthesis, we used the specific MEK inhibitor, AZD6244 [29] , which completely blocked PE-induced ERK activation (phosphorylation; Fig. 4A ). Consistent with earlier data obtained using other MEK inhibitors [2] [3] [4] , AZD6244 also largely inhibited activation of mTORC1 signaling as manifested by decreased phosphorylation of S6(Ser240/244).
AZD6244 did not significantly affect basal 18S rRNA transcription (Fig. 4B) Pol I machinery [36] ), which is caused by some other MEK inhibitors [37, 38] (Fig. 4A) .
A second MEK inhibitor, PD184352 [39] , also completely blocked PE-induced 5S and 18S rRNA synthesis, without affecting basal synthesis rates, confirming the importance of MEK in this response (Suppl. Fig. S2 ). However, because PD184352 is one of the MEK inhibitors that can activate AMPK, we did not use this compound further in this study.
Enhances rRNA synthesis via p90 RSK s
To assess which signaling components mediate activation of Pol I and Pol III downstream of MEK/ERK, we used BI-D1870, a potent and selective inhibitor of the four p90 RSK isoforms [30] . Earlier data (discussed in [40] ) indicate that p90 RSK2/3 are the main isoforms in ARVC. Our data (Fig. 5A ) confirm this and that their levels are not altered by PE (Fig. 5A ). p90 RSK s are activated by ERK [14] and we previously showed that PE rapidly activates p90 RSK s in ARVC [4] , and that BI-D1870 blocks signaling through p90 RSK s in these cells [41] , as it also does in neonatal cardiomyocytes [42] . BI-D1870 did not impede activation of ERK by PE (Fig. 5B) ; rather, it potentiated it, likely because it blocks an inhibitory feedback loop, as reported earlier [30, 41] . Extended treatment of ARVC with BI-D1870 (for 24 h) caused a decrease in the levels of p90
RSK2
, but not p90 RSK3 (Fig. 5A ). This may reflect a destabilizing effect of BI-D1870 on its target, the p90 RSK2 protein, but could reflect an additional effect of this compound. This effect was not observed in earlier studies where cells were only treated for shorter periods with this compound (e.g., [30] ). BI-D1870 did not affect basal labeling of 5S or 18S rRNA, but completely blocked the stimulation by PE (Figs. 5C,D) , indicating that activation of Pol I and Pol III by PE requires an obligatory input from p90 RSK s. One potential caveat is that BI-D1870 can also interfere with activation of PKB [41, 43] ; however, PE does not activate PKB in ARVC( [2] and Figs. 1A ,5B).
To extend these data, we also used an additional p90 RSK inhibitor, SL0101 [44] although this compound is a much less potent inhibitor of p90 RSK s as judged from in vitro data [45] . We therefore employed it at a higher concentration than for BI-D1870 (50 μM, the concentration generally used in other studies). As shown in Figs. 5E,F, SL0101 strongly inhibited the activation of 18S and 5S rRNA synthesis caused by PE, but without affecting basal synthesis rates. The latter observation indicates it very unlikely to affect uridine uptake, while the observed inhibition of the effect of PE supports the conclusion that p90 RSK s play a key role in mediating the activation of rRNA synthesis in response to PE. The incomplete inhibition likely reflects the lower potency of this inhibitor, and is consistent with the observation (Suppl. Fig. S3 ) that, while BI-D1870 strongly inhibits the PE-induced phosphorylation of the p90 RSK substrate GSK3, SL0101 only does so to a lesser extent. Given we already have to use a relatively high concentration of SL0101, we were reluctant to test it at even higher levels, where it may well exert off-target effects. An earlier study suggested that p90 RSK may regulate the activity of Pol I by phosphorylating TIF-1A [46] . While this may explain the ability of BI-D1870 to inhibit 18S rRNA synthesis, it does not explain the equally strong inhibition of 5S synthesis (Fig. 5D ). Since the assembly of new ribosomes requires all four rRNAs, three of which are derived from the same precursor as 18S rRNA, it was possible that inhibition of the activation of Pol I indirectly affected the stability of new 5S rRNA, perhaps because it cannot be incorporated into new ribosomes without the other rRNAs. To test this possibility, we configured the 4SU labeling experiment as a pulse-chase protocol (Fig. 6A) . The data clearly show that BI-1870 causes the decay of new 18S rRNA and 5S rRNA. This effect is similar to the effects of rapamycin-induced inhibition of rRNA synthesis in HeLa cells, which also promotes decay of new rRNA [17] and may explain the observed inhibition of the accumulation of new 5S rRNA seen here. It is potentially relevant that p90 RSK s are reported to regulate mTORC1 signaling [47] [48] [49] . However, our earlier data revealed that BI-D1870 does not interfere with activation of mTORC1 by PE in ARVC [41] . Thus, p90
RSK s control PE-stimulated rRNA transcription in ARVC directly, rather than via mTORC1. Interestingly, PE induces nuclear translocation of p90 RSK in neonatal cardiomyocytes [50] .
Earlier work implied that p90 RSK s phosphorylate Ser649 in the C-terminus of TIF-1A [46] ; however, there is no consensus phosphorylation site for the N-terminal kinase domain of these enzymes in this region of TIF-1A, leading those authors to suggest that phosphorylation was catalysed by the C-terminal kinase domain (which functions to activate the N-terminal kinase domain, which in turn transphosphorylates other proteins). However, BI-D1870 inhibits the N-terminal, not the C-terminal, domain of p90 the proposed ERK site at Ser633 (human numbering), the local sequence around the proposed p90 RSK -regulated site does not match the consensus for these kinases and differs significantly between these species (see Fig. 4B of [46] ). It seems likely that p90 RSK s regulate Pol I by phosphorylating another substrate. Identifying it requires substantial additional work, which is unfeasible in ARVC. Our observation that BI-D1870 completely inhibits the PE-activated synthesis of both 18S and 5S rRNA, while also causing hyperactivation of ERK, shows that the p90 RSK s play a dominant role in controling rRNA synthesis in ARVC. Since BI-D1870 clearly inhibits the induction of rRNA synthesis by PE, we asked whether it also interfered with the rapid activation of protein synthesis by PE. At times up to about 2 h, we have already shown that this effect is mediated by MEK/ERK signaling [2, 5, 6] . ARVC were incubated with or without PE for 24 h; [ 35 S]methionine was added 30 min after PE (where added). BI-D1870 clearly does not impede PE-stimulated protein synthesis; in fact, if anything, it causes an increase (Suppl. Fig. 4A ), perhaps reflecting its ability to enhance ERK phosphorylation, first reported in [30] and observed in Suppl. Figs. 4B and Fig. 5B . Thus, at relatively short times up to 24 h, the activation of protein synthesis by PE presumably reflects control of the activities of components of the translational machinery (e.g., the initiation and elongation factors which are rapidly stimulated by PE [2, 5] ), rather than increased ribosome content. Indeed, the present data show that rRNA synthesis is only activated slowly in ARVC. Ribosome levels do increase at longer times in hypertrophying neonatal cardiomyocytes [51, 52] or in vivo [7] and this effect is presumably important for the sustained faster rates of protein synthesis that lead to cardiac hypertrophy.
BI-D1870 inhibits the PE-induced recruitment of Pol I to the rRNA promoter
Since BI-D1870 clearly inhibits the PE-induced synthesis of new 18S rRNA, we used ChIP analysis to ask whether PE promoted the association of Pol I with the rDNA promoter and whether BI-D1870 affected this. We immunoprecipitated Pol I and used three different sets of primers (Fig. 7A ) to study its association with different parts of the rDNA promoter. PE greatly enhanced the association of Pol I with the rRNA promoter and this effect was essentially eliminated by prior treatment of ARVC with BI-D1870 (Fig. 7B) . Similar data were obtained for each pair of pair of primers, confirming that signaling through p90 RSK s is required for PE-induced recruitment of Pol I to the 45S rRNA promoter. Since PE does not increase UBF levels (Fig. 1D) , these data suggest that PE acutely regulates the function of UBF or other components of the Pol I transcriptional machinery.
Concluding remarks
This is the first study of the signaling events that control rRNA synthesis in adult cardiomyocytes. It shows that the hypertrophic agonist PE stimulates the synthesis of rRNA in adult rat cardiomyocytes, consistent with much earlier data showing that hypertrophy is associated with increased cardiac ribosome content and faster ribosome synthesis [7] . We show that PE stimulates the synthesis of both 5S rRNA, made by Pol III, and 18S rRNA, made by Pol I. It is important to note that our data indicate that MEK/ERK/p90 RSK signaling, rather than signaling through mTORC1, drives rRNA synthesis in response to hypertrophic stimulation of ARVC. This finding both differentiates the control of rRNA synthesis from other settings where mTORC1 appears to play a major role [9] and also raises the possibility that this pathway may also promote rRNA synthesis in other situations, e.g., cancer cells where the corresponding pathway is activated due to oncogenic mutations in Ras or Raf. We note that p90 RSK s regulate the sodium/proton exchanger (NHE-1) in cardiomyocytes (reviewed in [53] ) and that the NHE-1 is implicated hypertrophy ( [54] ). It will be important to investigate the possible role of NHE-1 in regulating rRNA synthesis, e.g., via alterations in intracellular pH. Interestingly, just prior to submission of this article, p90 RSK3 was
shown to be required for cardiac hypertrophy in neonatal cardiomyocytes and in vivo in response to pressure overload [55] , although the molecular mechanism(s) underlying its contribution to this process was not determined. Here, we demonstrate that p90 RSK s play a key role in the activation of rRNA synthesis in response to hypertrophic stimulation. Increased ribosome biogenesis is likely to be important for the sustained increases in protein synthesis that underlie cardiomyocyte growth. Our data thus appear consistent with the findings from other groups that p90 RSK inhibitors hypertrophy in block neonatal myocytes [42, 50, 55] . It is now clearly important to establish how p90 RSK s activate rRNA synthesis in ARVC; insights into this may provide opportunities for intervention to prevent or reverse cardiac hypertrophy.
Supplementary data to this article can be found online at http:// dx.doi.org/10.1016/j.yjmcc.2013.03.006.
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